Morinaga B-3™

 

Bifidobacterium is a well-studied genus of beneficial bacteria that naturally inhabits the human gut. There are many species of bifidobacteria, and, like all probiotics, their health benefits are strain-specific. Bifidobacterium breve is a species of bifidobacteria commonly found in the intestines of newborn infants. Morinaga B-3 is a clinically backed, room-temperature-stable strain of Bifidobacterium breve that has been shown to support various aspects of healthy metabolism.*[i],[ii]

A recent placebo-controlled human clinical study, which followed subjects for 12 weeks, showed that Morinaga B-3:

  • Promotes weight loss after 12 weeks of supplementation compared to baseline*
  • Reduces body fat after 12 weeks of supplementation compared to baseline and placebo*
  • Supports healthy liver function*

These results were presented at the 67th Annual Meeting of the Japan Society of Nutrition and Food Science. They confirm the findings of previous animal research, which show that Morinaga B-3 supports a healthy weight and body fat percentage, and additionally helps maintain blood glucose, insulin and cholesterol levels already within a normal range*

 

 

 

STATUS

FUNCTIONS


    MECHANISM OF ACTION

    In vitro studies suggest that Morinaga B-3 has the potential to improve intestinal barrier function.*[iii]

    SAFETY

    Bacteria of the Bifidobacterium genus occur naturally in the human gut and are associated with good health.* The safety of Morinaga B-3 was fully confirmed by oral toxicity tests, analysis of antibiotic resistance and genomic analysis. Additionally, in human clinical research on Morinaga B-3, no serious adverse effects have been reported.[iv]

    [i] Morinaga Milk Industry Co, Ltd. Tokyo. Presented at 67th Annual Meeting of Japan Society of Nutrition and Food Science. Nagoya University. 2013, May 24-26.

    [ii]  Study of Bifidobacterium breve B-3. Unpublished study.

    [iii] Morinaga Milk Industry Co, Ltd. Tokyo. Presented at 67th Annual Meeting of Japan Society of Nutrition and Food Science. Nagoya University. 2013, May 24-26.

    [iv] Study of Bifidobacterium breve B-3. Unpublished study.